We comprehensively studied the cellular immune response during acute human hepatitis C virus (HCV) infection by monthly prospective sampling of persons at high risk of infection. In 19 of 23 subjects, interferon-gamma–secreting T cells specific for 1 or more peptides spanning the entire HCV polyprotein were detected 1 to 3 months after infection. The median time to development of interferon gamma responses to HCV peptides was 33 days (range, 29-50 days), and these responses peaked between 180 and 360 days. Nineteen subjects had sufficient follow-up to determine outcome, with 15 (79%) developing persistent viremia and 4 (21%) clearing viremia spontaneously. Of those with progression to chronic infection and detectable T cell responses, all lost recognition of one or more antigens recognized during acute infection, and the median reduction in the magnitude of responses was 85%. Most significantly, despite ongoing viremia, those who had persistent infection did not develop new epitope specificities after the first 6 months of infection. In conclusion, in most individuals, the CD8+ T cell responses generated early in HCV infection decline in peripheral blood and are not replaced with new responses. Supplementary material for this article can be found on the HEPATOLOGY website (http://www.interscience.wiley.com/jpages/0270-9139/suppmat/index.html). (HEPATOLOGY 2005;42:104–112.)

The World Health Organization estimates there are 170 million persons with hepatitis C virus (HCV) infection worldwide, and an estimated 4 million persons are infected with HCV in the United States.1, 2 In most countries, HCV infection is found in 1% to 2% of the general population and may cause cirrhosis or hepatocellular cancer.3-6 Despite the high prevalence of HCV infection, acute HCV infection is difficult to study, because it is usually asymptomatic and most infections are due to injection drug use.4 Most studies of acute hepatitis C have investigated infection that occurred from transfusion or, less commonly, from needle stick exposure among health care workers.7-11 Although these studies have provided valuable information about acute HCV infection, they may not be representative of the major mode of acquisition.

Approximately 20% of patients resolve acute HCV infection, but the immune correlates that determine whether a patient resolves infection or proceeds to chronic infection are not well defined. Previous studies have shown that spontaneous clearance of HCV infection occurs in association with a broadly specific and vigorous cellular immune response.12-15 In contrast, chronic infection is characterized by low frequencies of CD8⁺ T cells in peripheral blood.16-21 Although the cellular immune response may be less vigorous and more narrowly directed in those who fail to clear the infection, a cellular immune response is nonetheless often present in early infection and may even persist into chronic infection. Why those immune responses fail to control infection is unclear, but responses generated in acute infection have been shown to decline in a few subjects who remained persistently infected.22, 23 Because of the small numbers of epitopes and subjects tested, previous studies have not fully established the breadth of initial and subsequent cellular responses or the loss of antigen recognition with progression to chronic infection.

To obtain longitudinal data on a large number of subjects representing the most common mode of HCV acquisition, we prospectively studied injection drug users (IDUs) at risk for HCV infection. In this cohort, we sought to define the interval during which new responses are formed, evaluate their breadth and vigor, and then assess their durability. We analyzed the cellular immune responses of IDUs to the entire HCV polyprotein from before infection through progression to chronicity to maximize the number of epitopes detected in our assessment of the timing of the development of a cellular response and potential loss of antigen recognition over time. Our results demonstrate that cellular immune responses are generated in most individuals during acute HCV infection, but the CD8+ T cell responses generated early in HCV infection decline in peripheral blood and are not replaced with new responses.

Abbreviations

HCV, hepatitis C virus; IDU, injection drug users; PBMC, peripheral blood mononuclear cells; RT-PCR, reverse transcription polymerase chain reaction; SFC, spot-forming cells.

Methods

Participants.

The Risk Evaluation Assessment of Community Health (REACH) prospective study of young IDUs in Baltimore, MD, examined the incidence and risk factors for HCV infection, as described previously.24 Participants eligible for the study were anti-HCV antibody negative, between 15 and 30 years of age, and acknowledged use of injection drugs. Participants were invited to co-enroll in a substudy of acute hepatitis C, and those who consented had blood drawn for isolation of serum, plasma, and peripheral blood mononuclear cells (PBMC) in a protocol designed for monthly follow-up. At each visit, participants were provided counseling to reduce the risks of drug use. None of the subjects in our cohort sought medical attention for symptoms during acute infection. All participants with acute HCV infection were offered treatment. None of the subjects in our cohort elected to be treated for HCV infection during the period of follow-up reported in this study. The REACH protocol and the HCV substudy protocols were approved by the institutional review boards of the Johns Hopkins Schools of Medicine and Hygiene and Public Health.

From 1997 to 2002, 179 participants were enrolled, and 62 (34.6%) developed anti-HCV antibodies (seroconverted). Beginning in November 2001, acutely infected persons were assessed for donation of ≈10⁸ to 10¹⁰ PBMC by blood donation or apheresis. HCV-specific lymphocyte responses were studied in detail in 23 acutely infected persons who were assessed frequently during the 6-month period after infection and from whom large volumes of PBMC were obtained. The 23 subjects were evaluated at a combined total of 486 (range, 8-45) visits.

HCV Testing Protocol.

Serum or plasma, stored at −80°C, from monthly follow-up visits was tested for the presence of HCV-specific antibodies using the commercially available Ortho version 3.0 ELISA (Ortho Clinical Diagnostics, Raritan, NJ) according to manufacturer's instructions. Specimens in which antibodies were detected were retested in duplicate along with the participant's previous seronegative sample to identify seroconverters.

HCV RNA testing was performed on sera or plasma separated from blood within 2 hours of collection and stored at −80°C. For HCV seroconverters, HCV RNA testing was done on samples collected before seroconversion until a negative result was obtained and after seroconversion to evaluate the outcome of infection (viral persistence vs. clearance) by using quantitative, and if undetectable, qualitative HCV RNA tests that are described below.

HCV RNA Assays

Qualitative.

For detecting HCV RNA, we used the COBAS AMPLICOR™ Hepatitis C Virus Test version 2.0 (Roche Molecular Systems, Branchburg, NJ). A limit of detection of 50 (1.7 log₁₀) International Units (IU)/mL at >95% detection is reported for this assay.

Quantitative.

To determine concentration of HCV RNA in serum, we used a quantitative reverse-transcription polymerase chain reaction (RT-PCR) assay (COBAS AMPLICOR HCV Monitor version 2.0, Roche Molecular Systems). This assay has a lower limit of quantitation of 600 (2.8 log₁₀) IU/mL. When HCV RNA was not detected by using this assay, the sample was retested by using the Roche qualitative test.

HCV Genotyping.

Genotype was determined by performing phylogenetic analysis on Core-E1 region sequences of HCV obtained from the first viremic specimen. For most specimens, sequences were obtained from complementary DNA clones generated with a long amplicon RT-PCR method that has been described previously.25 For other specimens, genotype was determined by direct sequencing of RT-PCR products from the same Core-E1 region as previously described.26 Sequences were aligned using ClustalX27 and trimmed to equal length using BioEdit.28 The GTR+I+G analytical model (with parameters pinvar = 0.17 and alpha = 0.8) was selected, using the AIC criterion as implemented in ModelTest version 3.0629 and PAUP* version 4b10 (Sinauer Associates, Sunderland, MA). Phylogenetic trees were estimated using the neighbor-joining algorithm implemented in PAUP*, and robustness of clustering was tested using by bootstrap analysis.30

Biochemistry Tests.

Alanine aminotransferase (ALT) and total bilirubin measurements were performed using standard assays in The Johns Hopkins Hospital laboratory.

Viral Recovery.

HCV clearance was defined as the presence of anti-HCV with HCV RNA undetectable by the COBAS AMPLICOR qualitative assay in serum or plasma specimens from 2 or more consecutive visits obtained at least 300 days after initial detection of viremia. Persistence was defined as the persistent presence of anti-HCV with HCV RNA detectable by the qualitative or quantitative COBAS AMPLICOR assay in serum or plasma specimens obtained at least 300 days after initial viremia.31

Interferon-Gamma Elispot Assay.

Figure 1 illustrates a recursive method for comprehensive screening of large-volume specimens followed by detailed examination of frequently obtained specimens. HCV-specific CD8+ T-cell responses were quantified by Elispot assay by using peptides in a matrix format as previously described,32 except using 523 overlapping peptides (16-22mer peptides overlapping by 10 amino acids and designed to avoid prohibited C-terminal amino acids) spanning the entire HCV-H77 polyprotein (genotype 1a) as well as 73 peptides corresponding to optimal described cytotoxic T lymphocyte epitopes.33 The peptides were arrayed in 92 wells with 7 to 12 peptides per well and each peptide contained in two wells of the plate. Ninety-six–well polyvinylidene plates (Millipore, Billerica, MA) were coated with 2.5 μg/mL recombinant human anti-interferon gamma (IFN-γ antibody (Endogen, Pierce Biotechnology, Rockford, IL) in phosphate-buffered saline (PBS) at 4°C overnight. Previously frozen PBMC were thawed and added at 200,000 cellswell in 140 μL R10 media (RPMI 1640, Sigma-Aldrich Corp., St. Louis, MO; 10% fetal calf serum, Sigma-Aldrich; 10 μmol/L Hepes buffer, Sigma-Aldrich; 2 mmol/L glutamine; and 50 U/mL penicillin-streptomycin). Peptides were added directly to the wells at a final concentration of 10 μg/mL. The plates were incubated for 20 hours at 37°C, 5% CO₂. Plates were then washed, labeled with 0.25 μg/mL biotin-labeled anti-interferon gamma (IFN-γ) (Endogen), and developed by incubation with streptavidin-alkaline phophatase (Bio-Rad Laboratories, Hercules, CA) followed by incubation with BCIP/NBT (Bio-Rad) in Tris-buffer (pH 9.5). The reaction was stopped by washing with tap water, and the plates were dried then counted on an Immunospot plate reader (Cellular Technology Ltd, Cleveland, OH) For quantitation of ex vivo responses, the assay was performed at least in duplicate, and background was not more than 15 spot-forming cells (SFC)/10⁶ PBMC. Responses were considered positive if the number of spots per well minus the background was at least 25 SFC per million PBMC.32 The peptides recognized in the matrix were subsequently tested individually and in at least duplicate to confirm recognition and to measure the number of SFC produced. Intra-assay variability was less than 10%. A control of pooled cytomegalovirus, Epstein-Barr virus, and influenza antigens (control peptide pool) and phytohemagglutinin were used as positive controls.34 Responses to the pooled cytomegalovirus, Epstein-Barr virus, and influenza antigens control peptide pool were quantifiable and varied by no more than 30% among visits, with no temporal trend. Responses to PHA were uniformly positive.

Details are in the caption following the image — **Figure 1**
Open in figure viewer PowerPoint

Schema for comprehensive and longitudinal analysis of cellular immune responses to HCV. Prospectively collected specimens were tested for HCV RNA, and the date of onset of viremia was estimated as the midpoint between repeatedly negative and positive specimens. In step 1, large-volume specimens (depicted as triangles A, B, and C) were screened using overlapping peptides, depicted as a series of rectangles along the HCV genome map, and detected responses are depicted as distinct rectangles to the right. In step 2, all peptides eliciting a detectable response were used to determine the temporal course of recognition in monthly smaller-volume PBMC specimens (hypothetical results are depicted, meant to be analogous to Fig. 2). Occasional missed visits are illustrated by a gap between the visits at 45 and 105 days of viremia; “*” indicates no detected responses to any peptide when tested in a monthly specimen; “**” indicates a previously detected peptide response not detected at that screening visit. HCV, hepatitis C virus; PBMC, peripheral blood mononuclear cells.

Viral Sequence Analysis.

From 140 to 280 μL serum or plasma, the 5.2 kb region from the 5′UTR to the NS3/NS4A junction was cloned as previously described.25 For each specimen, 33 clones were assigned to clonotypes by using a previously described gel shift assay,35 and 2 clones representing the modal clonotype were sequenced, with a third clone used as needed to resolve discrepancies. Sequences were assembled into contiguous sequences using Aligner (CodonCode, Dedham, MA). Sequence data were obtained at the point of initial viremia and approximately 6 months later.

Statistical Analysis.

Descriptive statistical methods were used to analyze and present the data. To guide interpretation, statistical inferences were made by using the chi square or Fisher's exact tests for categorical variables and by using non-parametric rank-sum tests for continuous variables. A P value of less than .05 was considered statistically significant.

Results

Quantitation of Elispot Responses.

HCV-specific lymphocyte responses were studied in 23 acutely HCV-infected persons who were assessed frequently during the 18 months after infection. The mean duration of follow-up, the mean age at seroconversion, the genotypes, and the gender and racial composition of the subjects are shown in Table 1. Cellular immune responses to HCV were examined in the acutely infected subjects using an Elispot assay for the detection of gamma interferon production and a combination of previously identified optimal CD8+ T-cell epitopes and overlapping peptides covering the whole HCV polyprotein as potential antigens. Nineteen subjects (83%) had detectable responses to HCV, and the median number of antigens recognized was 4 (range, 0-10), using the time point for each subject at which the largest number of antigens was recognized. Failure to recognize any epitopes was not attributable to mismatch of HCV subtypes, because three of the four subjects who did not recognize any epitopes were infected with genotype 1a virus.

Table 1. Characteristics of 23 Subjects With Acute HCV Infection

Mean age seroconversion in years (range)		24 (18-31)
Mean duration of follow-up months (range)		27 (12-47)
Gender n (%)	Male	16/23 (69)
	Female	7/23 (31)
Race n (%)	White	21/23 (92)
	African American	1/23 (4)
	Asian	1/23 (4)
Genotype n (%)	1a	18/23 (79)
	1b	2/23 (9)
	3a	1/23 (4)
	Mixed 1a and 1b	1/23 (4)
	No viremia detected*	1/23 (4)
Outcome**	Spontaneous clearance of viremia	4/19 (21)
	Persistent viremia	15/19 (79)

* One subject seroconverted with no detectable viremia at any visit and presumably became viremic and cleared in the interval between sampling.
** Duration of follow-up was sufficient at the time of analysis to determine outcome for 19 of the 23 subjects.

Nineteen of the 23 subjects tested had sufficient follow-up at the time of analysis to determine the outcome of infection (including 15 of the 19 with and all 4 of the subjects without detectable responses), of whom 15 (79%) remained persistently viremic and 4 (21%) subjects cleared viremia. There were no significant differences detected between those who cleared and those who were persistently infected in duration of follow-up, age at seroconversion, gender, race, or genotype. Four subjects with no detectable responses, and 11 subjects with detectable responses, developed persistent infection. The median number of epitopes recognized by those who developed persistent viremia was 4 (range, 0-10), not significantly different from the number recognized by those who cleared viremia spontaneously, which was 5 (range, 4-8). Although some CD4+ T cell responses were detected, more than 90% of the responses detected were CD8+ T-lymphocyte derived (data not shown).

Patterns of Cellular Immune Responses, Viremia, and Liver Biochemistry.

Patterns of cellular immune responses, viremia, and ALT levels over time are shown for 4 subjects in Fig. 2, and similar results for 5 additional subjects are available in Supplemental Figure S1 (available at: http://www.interscience.wiley.com/jpages/0270-9139/suppmat/index.html). Subject 18 cleared viremia more than 500 days after the onset of viremia, associated with a broad and sustained cellular immune response to 7 or 8 peptides (3 adjacent overlapping peptide responses indicate recognition of at least 2, and possibly 3, distinct epitopes). Viral genomic sequences obtained 0, 6, and 12 months after the onset of viremia were much more similar than sequences from distinct study subjects (data not shown), arguing against clearance and repeated infection at 200 days. Subject 17 developed chronic infection with a low level of viremia (300-2500 IU/mL), with transient control of viremia (below the limit of detection) at 138 days associated with an broad and vigorous cellular immune response to 7 peptides, which became progressively narrower and less intense, with the remaining 4 responses only at the limit of detection at 713 days. Subject 24 developed chronic higher-level viremia (400,000-600,000 IU/mL) associated with a delayed and initially narrow cellular immune response, with loss of 1 of 5 responses at day 572. Subject 29 developed chronic high-level viremia (500,000-2,000,000 IU/mL) associated with a delayed, narrow, and non-sustained cellular immune response.

Anti-HCV cellular immune responses appeared approximately 1 month after infection. For 7 subjects with PBMC available before initial viremia, cellular responses were not detected before viremia. Thus, all the responses measured were virus infection dependent. Assuming that cellular responses initially occurred midway between the visit with no detectable response and the visit in which responses were first detectable, we estimated the median time from onset of viremia to development of detectable responses for these subjects was between 29 and 50 days (mean, 38; median, 33). Cellular responses were not detected in the first viremic specimen from any subject during monthly follow-up, though it is likely that some of them were viremic for 2 to 4 weeks before this assessment. The lag between HCV infection and detection of functionally active HCV-specific T cells was longer than has been reported for other viruses that infect humans36-39 and is consistent with the data in a previous report of acute HCV infection.11

Reduced Peripheral CD8+ T Cell Responses After the Acute Phase.

In most subjects who progressed to chronic infection, viremia persisted despite detectable CD8+ lymphocyte responses to multiple epitopes for years. Although CD8+ lymphocyte responses to some epitopes were detectable for years, the level of antigen recognition declined over time. As shown in Fig. 2, responses peaked between 100 and 400 days after infection and declined from that peak with progression to chronic infection. For seven subjects with detectable cellular immune responses who progressed to chronic infection and were followed for more than 500 days, the Elispot responses at peak recognition and at the last time point tested are shown in Fig. 3A. In those who progressed to persistent infection, the median number of SFC per million PBMC at peak was 170 (range, 25-900), and it was 25 (range, 0-380) at the latest point screened, which occurred at least 1 year after infection. This represents a decrease in magnitude of recognition of 85% with progression to chronic infection. In subjects who cleared viremia, median peak recognition was similar at 175 SFC per million PBMC (range, 90-1,135), and decreased to a median of 95 (range, 50-1,135), a decrease in magnitude of 46%. In addition to a decline in the magnitude of response with progression to chronicity, we also observed declining breadth of response. After an initial increase in the number of antigens recognized in the first 180 days of infection, there was progressive loss in the number of antigens recognized, as shown in Fig. 3B. Between 290 and 514 days after infection, complete loss of recognition of 1 or more antigens recognized during acute infection was observed in all nine subjects who progressed to chronic infection (Table 2). In contrast, neither of the two subjects who cleared infection and were followed for over 500 days lost recognition of any epitopes. It is possible that T cells specific for the antigen were not lost completely but fell below the limit of detection of our assay. However, we were also unable in two attempts to expand a population of cells specific for the antigen even with prolonged incubation. Interestingly, loss of antigen recognition was not observed until more than 290 days after initial viremia, long after most subjects who clear their viremia have eliminated HCV from the bloodstream (Table 2).

Table 2. Loss of Antigen Recognition With Progression to Chronic Infection in Subjects With Cellular Immune Responses During Acute Infection

Subject	Number of Responses	Peak of Response*	First Ag Lost (days)
17	8	138	290
24	5	135	541
28	10	236	425†
29	3	135	513
30	4	134	400
45	4	340	363
49	5	398	514
52	2	213	321
54	4	246	376
Median	4	213	400

* Days of viremia at which the sum of the ELISpot responses (expressed as SFC per million PBMC) was maximal.
† Ab negative and HCV RNA positive on entry to the study. The estimated initial detection of antigen was determined by subtracting 5 weeks (average time to seroconversion32) from the initial detection of antibody.

No new epitope specificities developed after the first 6 months of infection, as shown in Fig. 4. Of the 38 T cell responses detected in the subjects who developed chronic infection, only 1 was first identified more than 6 months after initial viremia in any subject despite ongoing viremia. That 1 outlier was detected in subject 28 at 217 days, after a gap in specimen collection of 120 days, and therefore may have elicited a response at any time between 97 and 217 days after the onset of viremia.

Change in Viral Amino Acid Sequence.

To address the possibility that the observed failure to develop new T cell specificities might be attributable to lack of viral sequence evolution, sequencing of most of the HCV genome was performed for 8 subjects, using specimens from initial viremia and 6 months later. Viral amino acid sequence changes were observed in all 8 subjects. The median number of amino acid substitutions was 11 (range, 2-12) per subject in the 1,651 residue region sequenced.40

Discussion

This study represents an assessment of T cell responses against oligopeptides, spanning every viral protein from the acute to chronic phase. In this investigation, the breadth of the response was set early in infection, and, even in persons with ongoing infection, no new responses were formed, and early responses became undetectable. Those subjects without a detectable cellular immune response uniformly progressed to chronic viremia.

In those with viral persistence despite immune responses directed against HCV epitopes, the mechanisms for immune failure remain unclear. This failure may be attributable to impaired cellular effector functions (proliferation, cytokine secretion, or cytolytic activity) or T cell exhaustion, as has been suggested by previous data.11, 41 We observed a delay in the development of T cell responses to HCV infection relative to other viral infections; however, we also observed this delay in those who cleared infection. There was no qualitative difference between those who cleared infection and those with persistence in terms of the breadth or magnitude of response during the acute phase. We did see decline in and loss of antigen recognition over time in all of the subjects who remained persistently infected, but this decline occurred substantially later than the disappearance of viremia in those with clearance. The earliest point at which we noted complete loss of recognition of any antigen was almost 300 days after initial detection of HCV and most of our subjects who have cleared viremia did so within 90 days of onset.

The number of subjects in the study who cleared infection was too small and the sampling around the time of clearance too infrequent to conclude that clearance is associated with preservation of responses whereas progression to chronicity is associated with declining recognition. In addition, some of the antigens targeted during acute infection were still recognized by chronically infected subjects years after HCV infection. Thus, although exhaustion and impairment of T-cell function may play an important role, they are unlikely to represent the only mechanisms for persistence of HCV infection and may be a consequence of continued antigenic stimulation rather than the cause of persistent viremia. Given that HCV quasispecies complexity increases over time and the finding that viremia persists for years in the presence of HCV-specific T lymphocytes, it is possible that the T lymphocytes are no longer effective because the virus has mutated such that the target antigen is no longer present.42

Whereas viral escape could explain the failure of some T cell specificities, antigen variation could be expected to generate potential new target antigens; however, such responses were not observed. Despite recognition of a combined 51 antigens and ongoing viremia with sequence evolution, no antigens were first recognized more than 6 months after infection in any subject. In contrast, new responses to HIV-1 and HTLV-1 have been detected after the first 6 months of infection,43, 44 suggesting that HCV may interfere with this process in some way.

There are several possible explanations for the immune system's failure to generate new responses over the course of infection as viral quasispecies diversification occurs. First, chronic HCV infection may be associated with induction of suppressor T-cells, as has been suggested in a prior study.45 An alternative hypothesis is that chronic HCV infection is associated with dendritic cell dysfunction, as has been suggested in other studies.47, 48 However, patients with chronic HCV are not demonstrably immunosuppressed and mount cellular immune responses to other infections. Therefore, the mechanism for the failure to generate new responses to HCV antigens is likely to be HCV-specific. A hypothesized mechanism of HCV-specific immunosuppression is that viral evolution results in sequences that are similar enough to the initial sequence that T lymphocytes recognizing the original sequence are activated rather than naïve cells that would potentially generate more effective responses to the new sequence. This concept of “original antigenic sin” has been shown to occur after sequential infection of mice with two similar strains of lymphocytic choriomeningitis virus, but has not been demonstrated in evolution from acute to chronic infection.48 Anti-HCV immune responses may also be compartmentalized to the liver, as some studies suggest,49-51 although others have found that specificities in the 2 compartments are similar, and studies of intrahepatic lymphocyte responses during acute human HCV infection are lacking. Recent evidence suggests that CD4+ T cell help is required for efficient development of effector and memory CD8 T cell populations in HIV infection,52 and when lacking may facilitate viral escape mutation in HCV infection.53

Although other studies have demonstrated HCV-specific gamma interferon production in IDUs in the absence of HCV antibodies or viremia, we did not find any HCV-specific gamma interferon production before the onset of viremia in our subjects.54, 55 However, the number of subjects we assessed for responses before viremia was relatively small, because the primary purpose of this study was not to assess subjects for cellular responses in the absence of viremia. In addition, all of our subjects were viremic initially and ultimately developed antibodies, and most became persistently infected. In contrast, the subjects in whom cellular responses were detected in the other studies failed to seroconvert or acquire chronic HCV infection. It has been hypothesized that the responses seen in subjects who never have detectable antibody or HCV may confer protective immunity.54, 55 Failure to find cellular responses before infection in our subjects is consistent with that hypothesis because those who progress to chronic HCV infection would not be expected to have markers of protective immunity.

In conclusion, these data are representative of most HCV infections not only because the mode of acquisition for these subjects represents the major mode of HCV infection in the Western world, but also because the subjects were studied prospectively without regard to symptoms before, during, and after infection. The results significantly expand the available data on induction and maintenance of an HCV specific cellular immune response. In addition, this comprehensive longitudinal analysis of CD8+ T cell responses against all viral proteins represents the first such assessment in any human viral infection during the transition from acute to chronic infection and sheds light on evolution of immune responses with prolonged antigenic exposure. Determining the mechanisms that permit viral persistence despite measurable cellular immune responses to multiple epitopes and that interfere with development of new responses could improve efforts to prevent and treat chronic viral infections.

Acknowledgements

The following reagent was obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: CEF Control Peptide Pool from Dr. Josephine Cox and Dr. Jeffrey Currier.

Supporting Information

This article includes Supplementary Table and Figures available at http://www.interscience.wiley.com/jpages/0270-9139/suppmat

Filename

Description

jwsHEPv42.1.104.tbl1.doc44.5 KB

>Peptide antigens recognized by at least one of 23 subjects with acute HCV infection.

jwsHEPv42.1.104.fig1.doc75.5 KB

Levels of CTL response and HCV RNA during acute HCV infection in 5 individuals. <br /> <br /> Subject 51 seroconverted by EIA testing during a 240 day interruption in sampling, and apparently cleared viremia during that interval. Subjects 45, 49, 52, and 54 progressed to chronic infection. The legend indicates peptide position (relative to H77 polyprotein, Genbank accession #AF009606) and sequence. Responses below 25 SFC per million PBMC are not shown. CTL responses were measured by IFN&00b7; Elispot; "*" indicates no responses were detected to any peptide recognized in other specimens. HCV RNA levels below the limit of quantitation are plotted at 50 IU/mL; "-" indicates specimens were also negative for HCV RNA by qualitative assay. The point of initial viremia was estimated as the midpoint between the last sample with undetectable HCV RNA and the first sample with detectable HCV RNA, or in the case of subject 51 (in whom viremia was not detected), onset of infection was estimated as the midpoint between EIA negative and positive visits.

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

References

1 World Health Organization. Hepatitis C: global prevalence. Weekly Epidemiological Record 1997; 72: 341–348.
PubMed Google Scholar
2 Alter MJ. Epidemiology of hepatitis C. HEPATOLOGY 1997; 26(3 Suppl 1 ): 62S–65S.
10.1002/hep.510260711
CAS PubMed Web of Science® Google Scholar
3 Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995; 15: 5–14.
10.1055/s-2007-1007259
PubMed Web of Science® Google Scholar
4 Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morb Mortal Wkly Rep 1998; 47: 1–39.
Google Scholar
5 Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. HEPATOLOGY 1999; 29: 908–914.
10.1002/hep.510290311
CAS PubMed Web of Science® Google Scholar
6 Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463–1466.
10.1056/NEJM199506013322202
CAS PubMed Web of Science® Google Scholar
7 Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B, et al. A long-term study of hepatitis C virus replication in non-A, non- B hepatitis. N Engl J Med 1991; 325: 98–104.
10.1056/NEJM199107113250205
PubMed Web of Science® Google Scholar
8 Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. HEPATOLOGY 1995; 21: 639–644.
10.1002/hep.1840210306
CAS PubMed Web of Science® Google Scholar
9 Garson JA, Tuke PW, Makris M, Briggs M, Machin SJ, Preston FE, et al. Demonstration of viraemia patterns in haemophiliacs treated with hepatitis C virus contaminated factor VIII concentrates. Lancet 1990; 336: 1022–1025.
10.1016/0140-6736(90)92487-3
CAS PubMed Web of Science® Google Scholar
10 Prince AM, Brotman B, Inchauspe G, Pascual D, Nasoff M, Hosein B, et al. Patterns and prevalence of hepatitis C virus infection in posttransfusion non-A, non-B hepatitis. J Infect Dis 1993; 167: 1296–1301.
10.1093/infdis/167.6.1296
CAS PubMed Web of Science® Google Scholar
11 Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194(10): 1395–1406.
10.1084/jem.194.10.1395
CAS PubMed Web of Science® Google Scholar
12 Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10: 439–449.
10.1016/S1074-7613(00)80044-8
CAS PubMed Web of Science® Google Scholar
13 Gruner NH, Gerlach TJ, Jung MC, Diepolder HM, Schirren CA, Schraut WW, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000; 181: 1528–1536.
10.1086/315450
CAS PubMed Web of Science® Google Scholar
14 Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191: 1499–1512.
10.1084/jem.191.9.1499
CAS PubMed Web of Science® Google Scholar
15 Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6: 578–582.
10.1038/75063
CAS PubMed Web of Science® Google Scholar
16 Hiroishi K, Kita H, Kojima M, Okamoto H, Moriyama T, Kaneko T, et al. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection. HEPATOLOGY 1997; 25: 705–712.
10.1002/hep.510250336
CAS PubMed Web of Science® Google Scholar
17 Rehermann B, Chang KM, McHutchison JG, Kokka R, Houghton M, Chisari FV. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 1996; 98: 1432–1440.
10.1172/JCI118931
CAS PubMed Web of Science® Google Scholar
18 Cerny A, McHutchison JG, Pasquinelli C, Brown ME, Brothers MA, Grabscheid B, et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 1995; 95: 521–530.
10.1172/JCI117694
CAS PubMed Web of Science® Google Scholar
19 He XS, Rehermann B, Lopez-Labrador FX, Boisvert J, Cheung R, Mumm J, et al. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A 1999; 96(10): 5692–5697.
10.1073/pnas.96.10.5692
CAS PubMed Web of Science® Google Scholar
20 Shirai M, Okada H, Nishioka M, Akatsuka T, Wychowski C, Houghten R, et al. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol 1994; 68: 3334–3342.
10.1128/JVI.68.5.3334-3342.1994
CAS PubMed Web of Science® Google Scholar
21 Battegay M, Fikes J, Di Bisceglie AM, Wentworth PA, Sette A, Celis E, et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 1995; 69: 2462–2470.
10.1128/JVI.69.4.2462-2470.1995
CAS PubMed Web of Science® Google Scholar
22 Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001; 75: 5550–5558.
10.1128/JVI.75.12.5550-5558.2001
CAS PubMed Web of Science® Google Scholar
23 Lechner F, Gruener NH, Urbani S, Uggeri J, Santantonio T, Kammer AR, et al. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 2000; 30: 2479–2487.
10.1002/1521-4141(200009)30:9<2479::AID-IMMU2479>3.0.CO;2-B
CAS PubMed Web of Science® Google Scholar
24 Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18(Suppl 1): S11–S19.
10.1097/00042560-199802001-00004
PubMed Web of Science® Google Scholar
25 Liu Z, Netski DM, Mao Q, Laeyendecker O, Ticehurst JR, Wang XH, et al. Accurate representation of the hepatitis C virus quasispecies in 5.2-kilobase amplicons. J Clin Microbiol 2004; 42: 4223–4229.
10.1128/JCM.42.9.4223-4229.2004
CAS PubMed Web of Science® Google Scholar
26 Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000; 182: 698–707.
10.1086/315786
CAS PubMed Web of Science® Google Scholar
27 Jeanmougin F, Thompson JD, Gouy M, Higgins DG, Gibson TJ. Multiple sequence alignment with Clustal X. Trends Biochem Sci 1998; 23: 403–405.
10.1016/S0968-0004(98)01285-7
CAS PubMed Web of Science® Google Scholar
28 Hall TA. BioEdit: biological sequence alignment editor for Windows 95/98/NT version 5.0.7. software 2001; Distributed by author: http://www.mbio.ncsu.edu/RNaseP/info/programs/BIOEDIT/bioedit.html.
Google Scholar
29 Posada D, Crandall KA. MODELTEST: testing the model of DNA substitution. Bioinformatics 1998; 14: 817–818.
10.1111/j.1095-8312.2004.00368.x
CAS PubMed Web of Science® Google Scholar
30 Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 1985; 39: 783–791.
10.2307/2408678
PubMed Web of Science® Google Scholar
31 Cox AL, Netski DM, Mosbruger T, Sherman SG, Strathdee S, Ompad DC, et al. Prospective evaluation of community-acquired acute Hepatitis C. Clin Infect Dis 2004; 40: 951–958.
10.1086/428578
Web of Science® Google Scholar
32 Lauer GM, Ouchi K, Chung RT, Nguyen TN, Day CL, Purkis DR, et al. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 2002; 76: 6104–6113.
10.1128/JVI.76.12.6104-6113.2002
CAS PubMed Web of Science® Google Scholar
33 Ward S, Lauer G, Isba R, Walker B, Klenerman P. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol 2002; 128: 195–203.
10.1046/j.1365-2249.2002.01840.x
CAS PubMed Web of Science® Google Scholar
34 Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002; 260: 157–172.
10.1016/S0022-1759(01)00535-X
CAS PubMed Web of Science® Google Scholar
35 Wang YM, Ray SC, Laeyendecker O, Ticehurst JR, Thomas DL. Assessment of hepatitis C virus sequence complexity by electrophoretic mobilities of both single- and double-stranded DNAs. J Clin Microbiol 1998; 36: 2982–2989.
CAS PubMed Web of Science® Google Scholar
36 Eichelberger M, Allan W, Zijlstra M, Jaenisch R, Doherty PC. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J Exp Med 1991; 174: 875–880.
10.1084/jem.174.4.875
CAS PubMed Web of Science® Google Scholar
37 Hou S, Doherty PC, Zijlstra M, Jaenisch R, Katz JM. Delayed clearance of Sendai virus in mice lacking class I MHC-restricted CD8+ T cells. J Immunol 1992; 149: 1319–1325.
CAS PubMed Web of Science® Google Scholar
38 Koup RA, Safrit JA, Cao Y, Andrew CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68: 4650.
10.1128/JVI.68.7.4650-4655.1994
CAS PubMed Web of Science® Google Scholar
39 Allen TM, O'Connor DH, Jing P, Dzuris JL, Mothe BR, Vogel TU, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000; 407: 386–390.
10.1038/35036559
CAS PubMed Web of Science® Google Scholar
40 Cox AL, Mosbruger T, Mao Q, Liu Z, Wang X-H, Yang H-C, et al. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 2005; 201: 1741–1752.
10.1084/jem.20050121
CAS PubMed Web of Science® Google Scholar
41 Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002; 169: 3447–3458.
10.4049/jimmunol.169.6.3447
CAS PubMed Web of Science® Google Scholar
42 Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001; 15: 883–895.
10.1016/S1074-7613(01)00245-X
CAS PubMed Web of Science® Google Scholar
43 Goulder PJ, Altfeld MA, Rosenberg ES, Nguyen T, Tang Y, Eldridge RL, et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 2001; 193: 181–194.
10.1084/jem.193.2.181
CAS PubMed Web of Science® Google Scholar
44 McGinn TM, Wei Q, Stallworth J, Fultz PN. Immune responses to HTLV-I(ACH) during acute infection of pig-tailed macaques. AIDS Res Hum Retroviruses 2004; 20: 443–456.
10.1089/088922204323048195
CAS PubMed Web of Science® Google Scholar
45 Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. HEPATOLOGY 2003; 38: 1437–1448.
10.1016/j.hep.2003.09.026
CAS PubMed Web of Science® Google Scholar
46 Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 2001; 120: 512–524.
10.1053/gast.2001.21212
CAS PubMed Web of Science® Google Scholar
47 Kanto T, Hayashi N, Takehara T, Tatsumi T, Kuzushita N, Ito A, et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 1999; 162: 5584–5591.
CAS PubMed Web of Science® Google Scholar
48 Klenerman P, Zinkernagel RM. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 1998; 394: 482–485.
10.1038/28860
CAS PubMed Web of Science® Google Scholar
49 Minutello MA, Pileri P, Unutmaz D, Censini S, Kuo G, Houghton M, et al. Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med 1993; 178: 17–25.
10.1084/jem.178.1.17
CAS PubMed Web of Science® Google Scholar
50 Thomson M, Nascimbeni M, Havert MB, Major M, Gonzales S, Alter H, et al. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 2003; 77: 862–870.
10.1128/JVI.77.2.862-870.2003
CAS PubMed Web of Science® Google Scholar
51 Grabowska AM, Lechner F, Klenerman P, Tighe PJ, Ryder S, Ball JK, et al. Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. Eur J Immunol 2001; 31: 2388–2394.
10.1002/1521-4141(200108)31:8<2388::AID-IMMU2388>3.0.CO;2-L
CAS PubMed Web of Science® Google Scholar
52 Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998; 188: 2199–2204.
10.1084/jem.188.12.2199
CAS PubMed Web of Science® Google Scholar
53 Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302: 659–662.
10.1126/science.1088774
CAS PubMed Web of Science® Google Scholar
54 Freeman AJ, French RA, Post JJ, Harvey CE, Gilmour SJ, White PA, et al. Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use. J Infect Dis 2004; 190: 1093–1097.
10.1086/422605
CAS PubMed Web of Science® Google Scholar
55 Mizukoshi E, Eisenbach C, Edlin B, Weiler C, Carrington M, O'Brien T, et al. HCV-specific cellular immune responses in subjects who are anti-HCV-negative, HCV RNA-negative despite long term (>15 years) injection drug use (AASLD Annual Meeting 2003 abstract #111). HEPATOLOGY 2003; 38(Suppl): 210A.
10.1016/S0270-9139(03)80154-4
PubMed Google Scholar

Citing Literature

Volume42, Issue1

July 2005

Pages 104-112

Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C^†

Abstract

Abbreviations